ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1105

New and Not Improved? The Efficacy Of FMS Medications

Robert S. Katz1, Hannah Bond2, Lauren Kwan2, Jessica L. Polyak2 and Susan Shott3, 1Rush Medical College, Chicago, IL, 2Rheumatology Associates, Chicago, IL, 3Rush University Medical Center, Chicago, IL

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: alternative medicine, Fibromyalgia and medication

  • Tweet
  • Email
  • Print
Session Information

Title: Fibromyalgia, Soft Tissue Disorders and Pain II

Session Type: Abstract Submissions (ACR)

Background/Purpose:   A wide variety of medications are used to treat FMS, with an equally wide variety of opinions about their efficacy. We asked FMS patients which medications they had tried for treating their disease, and how effective these medications were.

Methods: 150 office patients with FMS (130 women and 20 men; mean age 51 + 12) completed a questionnaire about the FMS medications they had taken and the effectiveness of these medications (rated as 1 = not helpful, 2 = mildly helpful, 3 = moderately helpful, and 4 = very helpful). The two-sided Friedman test was used to compare pairs of medications with respect to the ratings given by patients who had tried both medications, using a 0.05 significance level.

 Results: The following medications were tried by at least 40% of patients: NSAIDs (93%), prednisone (72%), Flexeril (64%), amitriptyline (64%), Norco/Vicodin (56%), Tramadol (50%), Lyrica (47%), Cymbalta (45%), and Ritalin (44%). The two least frequently tried medications were Vyvanse (9%) and nortriptyline (12%). Based on the percentage of patients who rated the medication as moderately or very helpful, the most helpful medications were Norco/Vicodin (75%), prednisone (70%), Ritalin (65%), Tizanidine (58%), NSAIDs (56%), phentermine (56%), amitriptyline (52%), Tramadol (50%), and Nuvigil/Provgil (50%). The least helpful medications were Savella (12%) and Lunesta (19%). Norco/Vicodin was significantly more helpful than Lyrica (median 4 vs. 1, p < 0.001), Cymbalta (median 4 vs. 1, p < 0.001), Flexeril (median 4 vs. 2, p < 0.001), Tramadol (median 4 vs. 2, p < 0.001), prednisone (median 4 vs. 3, p = 0.004), NSAIDS (median 3.5 vs. 2, p = 0.001), and amitriptyline (median 4 vs. 3, p = 0.041). Prednisone was significantly more helpful than Cymbalta (median 3 vs. 1, p < 0.001), Lyrica (median 3 vs. 1, p = 0.019), Flexeril (median 3 vs. 2, p = 0.028), and Tramadol (median 3 vs. 2, p = 0.009). Tramadol was significantly more helpful than Cymbalta (median 2 vs. 1, p = 0.018). Ritalin was significantly more helpful than Lyrica (median 3 vs. 1, p = 0.008), Cymbalta (median 3 vs. 1, p = 0.003), NSAIDs (median 3 vs. 2, p = 0.028), and Flexeril (median 3 vs. 2, p = 0.034). NSAIDs were significantly more helpful than Cymbalta (median 2 vs. 1, p = 0.001) and Lyrica (median 2 vs. 1, p = 0.020). Amitriptyline was significantly more helpful than Cymbalta (median 2 vs. 1, p = 0.005) and Lyrica (median 2 vs. 1, p = 0.033).

 Conclusion: Older medications were significantly more helpful for treating FMS than some newer medications. However, a wide variety of FMS medications may still be needed because different patients often respond to different medications.


Disclosure:

R. S. Katz,
None;

H. Bond,
None;

L. Kwan,
None;

J. L. Polyak,
None;

S. Shott,
None.

  • Tweet
  • Email
  • Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/new-and-not-improved-the-efficacy-of-fms-medications/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology